Immunogenicity of PCV24, an expanded pneumococcal conjugate vaccine, in adult monkeys and protection in mice

Safety, Tolerability, and Immunogenicity of a 20-Valent Pneumococcal Conjugate Vaccine (PCV20) in Adults 60 to 64 Years of Age

(2020) Donald Hurley et al.   CLINICAL INFECTIOUS DISEASES

Optimization and validation of a microcolony multiplexed opsonophagocytic killing assay for 15 pneumococcal serotypes

(2020) Katrina M Nolan et al.   Bioanalysis

Streptococcus pneumoniae serotype 3 is masking PCV13-mediated herd immunity in Canadian adults hospitalized with community acquired pneumonia: A study from the Serious Outcomes Surveillance (SOS) Network of the Canadian immunization research Network (CIRN)

(2019) Jason J. LeBlanc et al.   VACCINE

Phase 1 trial of a 20-valent pneumococcal conjugate vaccine in healthy adults

(2019) Allison Thompson et al.   VACCINE

Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged ≥65 Years: Updated Recommendations of the Advisory Committee on Immunization Practices

(2019) Almea Matanock et al.   MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT

Immunogenicity Comparison of a Next Generation Pneumococcal Conjugate Vaccine in Animal Models and Human Infants

(2019) Jinfu Xie et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naïve adults ≥50 years of age

(2018) Susan J. Ermlich et al.   VACCINE

Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016

(2018) Christopher Troeger et al.   LANCET INFECTIOUS DISEASES

Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV15) in healthy infants

(2018) David Greenberg et al.   VACCINE

Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine compared to 13-valent pneumococcal conjugate vaccine in adults ≥65 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine

(2018) James T. Peterson et al.   Human Vaccines & Immunotherapeutics

Immunogenicity differences of a 15-valent pneumococcal polysaccharide conjugate vaccine (PCV15) based on vaccine dose, route of immunization and mouse strain

(2017) Ivette Caro-Aguilar et al.   VACCINE

Pneumococcal serotype distribution: A snapshot of recent data in pediatric and adult populations around the world

(2017) Yadong A. Cui et al.   Human Vaccines & Immunotherapeutics

Invasive Streptococcus pneumoniae in Canada, 2011–2014: Characterization of new candidate 15-valent pneumococcal conjugate vaccine serotypes 22F and 33F

(2016) Alyssa R. Golden et al.   VACCINE

Pneumococcal Disease Prevention Among Adults

(2015) Tamara Pilishvili et al.   AMERICAN JOURNAL OF PREVENTIVE MEDICINE

Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance

(2015) Matthew R Moore et al.   LANCET INFECTIOUS DISEASES

Effects of Infant Pneumococcal Conjugate Vaccination on Serotype Distribution in Invasive Pneumococcal Disease among Children and Adults in Germany

(2015) Mark van der Linden et al.   PLoS One

Clinical Implications of Pneumococcal Serotypes: Invasive Disease Potential, Clinical Presentations, and Antibiotic Resistance

(2013) Joon Young Song et al.   JOURNAL OF KOREAN MEDICAL SCIENCE

Levels and functionality of antibodies after pneumococcal conjugate vaccine in schedules with different timing of the booster dose

(2013) Els van Westen et al.   VACCINE

Serotype-Specific Changes in Invasive Pneumococcal Disease after Pneumococcal Conjugate Vaccine Introduction: A Pooled Analysis of Multiple Surveillance Sites

(2013) Daniel R. Feikin et al.   PLOS MEDICINE

Serum IgM Antibodies Contribute to High Levels of Opsonophagocytic Activities in Toddlers Immunized with a Single Dose of the 9-Valent Pneumococcal Conjugate Vaccine

(2012) Birgit Simell et al.   Clinical and Vaccine Immunology

Biochemical, Genetic, and Serological Characterization of Two Capsule Subtypes amongStreptococcus pneumoniaeSerotype 20 Strains

(2012) Juan J. Calix et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Establishment of a New Human Pneumococcal Standard Reference Serum, 007sp

(2011) D. Goldblatt et al.   Clinical and Vaccine Immunology

A rhesus macaque model of Streptococcus pneumoniae carriage

(2011) M.T. Philipp et al.   JOURNAL OF MEDICAL PRIMATOLOGY

Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study

(2011) Elizabeth Miller et al.   LANCET INFECTIOUS DISEASES

Pre-clinical evaluation of a 15-valent pneumococcal conjugate vaccine (PCV15-CRM197) in an infant-rhesus monkey immunogenicity model

(2011) Julie M. Skinner et al.   VACCINE

The 13-valent pneumococcal conjugate vaccine (PCV13) elicits cross-functional opsonophagocytic killing responses in humans to Streptococcus pneumoniae serotypes 6C and 7A

(2011) David Cooper et al.   VACCINE

Older Adults Have a Low Capacity To Opsonize Pneumococci Due to Low IgM Antibody Response to Pneumococcal Vaccinations

(2010) Saeyoung Park et al.   INFECTION AND IMMUNITY

Cross-Reactivity of Current Serogroup 6 Factor Sera from Statens Serum Institut with the Recently Described Pneumococcal Serotype 6D

(2010) P. E. Bratcher et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Immunogenicity and Safety of 13-Valent Pneumococcal Conjugate Vaccine in Infants and Toddlers

(2010) S. H. Yeh et al.   PEDIATRICS

Antibodies to serotype 9V exhibit novel serogroup cross-reactivity following infant pneumococcal immunization

(2010) P.V. Licciardi et al.   VACCINE

Optimization and Validation of a Multiplex, Electrochemiluminescence-Based Detection Assay for the Quantitation of Immunoglobulin G Serotype-Specific Antipneumococcal Antibodies in Human Serum

(2009) R. D. Marchese et al.   Clinical and Vaccine Immunology